DNTH
Dianthus Therapeutics, Inc.About DNTH
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Cylvex Score
Caution
Multiple risk signals, limited coverage
Multi-factor score. Not a buy/sell signal.
Score history
CalibratingScore history appears after more daily scores
What goes into the score
6 axes · equal weightAnalystWall Street consensus & target distance
GrowthEarnings growth trajectory
ProfitabilityROE, margins, cash generation
ValuationPE, PEG, price-to-book ratios
TechnicalsPrice momentum & 52-week position
RiskBeta, volatility, leverage
The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.